Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
13 Marzo 2024 - 2:00PM
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on
meeting the significant unmet needs for women worldwide with a
broad portfolio of in-office, accessible and innovative therapeutic
and diagnostic products, announces it will participate in a
Fireside Chat with Jones Trading Analyst Catherine Novack to
discuss the current treatment landscape for infertility treatment
in women. Those interested in attending the event, which will be
held virtually on March 21, 2024 at 1PM ET, may register here.
Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James
Liu, M.D. will focus on the current treatment options in the
infertility services market, including Femasys’ FDA-authorized
FemaSeed device for intratubal insemination. During the event,
speakers will also examine emerging trends and technology that have
contributed to the growing utilization of assisted reproductive
technology (ART), as well as headwinds such as rising costs of IVF
in the current climate.
Ms. Lee-Sepsick is the founder of Femasys and has nearly three
decades of experience as a senior executive in the medical
technology industry. She is the lead inventor of the technologies
at Femasys and remains committed to advancing much needed
technology in women’s health. Prior to his role at Femasys, Dr. Liu
has served as Chairman, Department of Obstetrics and Gynecology at
University Hospital Health System, the Chair, Department of
Reproductive Biology at Case Western Reserve University, and the
Division Head, Reproductive Endocrinology and Infertility at the
University of Cincinnati.
About FemaSeedFemaSeed® is an
innovative infertility treatment designed to deliver sperm to the
fallopian tube where conception occurs. It is intended to enhance
natural fertilization and provide a first-line treatment option for
those seeking pregnancy. FemaSeed is less invasive and more
affordable than assisted reproduction procedures, such as IVF or
ICSI. FemaSeed achieved U.S. FDA clearance (September 2023) and
regulatory approval in Canada (April 2023) for patients seeking
insemination. At the end of the fourth quarter of 2023, Femasys
completed a pivotal clinical trial (LOCAL trial) for those seeking
intratubal insemination with a specific focus on male factor
infertility, a contributing factor in approximately 40-50% of
infertility cases. Top-line data from this study is planned for
release first quarter 2024 and will support the commercial launch
targeted for the first half of 2024.
About Femasys
Femasys is a biomedical company focused on meeting significant
unmet needs for women worldwide with a broad portfolio of
in-office, accessible solutions, including a lead revolutionary
product candidate and FDA-cleared, innovative therapeutic and
diagnostic products. Femasys’ FemBloc® permanent birth control
in late-stage clinical development is the first and only
non-surgical, in-office, permanent birth control method intended to
be a safer option for women at substantially less cost than the
long-standing surgical alternative. Femasys’
FemaSeed® Intratubal Insemination, an innovative infertility
treatment designed to deliver sperm directly where conception
occurs, is FDA-cleared and has received regulatory approval in
Canada. The Company has developed diagnostic products that are
complementary for which it has achieved regulatory approvals to
market in the U.S., Canada, and other ex-U.S. territories, and
which are commercial-ready due to its in-house manufacturing
capabilities. The Company’s diagnostic products include
FemVue® for fallopian tube assessment by ultrasound, which can
be used in conjunction with FemCath®, an intrauterine catheter for
selective fallopian tube evaluation, and FemCerv®, an endocervical
tissue sampler for cervical cancer diagnosis. Learn more at
www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements that are subject to
substantial risks and uncertainties. Forward-looking statements can
be identified by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “pending,” “intend,” “believe,”
“potential,” “hope,” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are
based on our current expectations and are subject to inherent
uncertainties, risks and assumptions, many of which are beyond our
control, difficult to predict and could cause actual results to
differ materially from what we expect. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could
cause actual results to differ include, among others: our ability
to develop and advance our current product candidates and programs
into, and successfully initiate, enroll and complete, clinical
trials; the ability of our clinical trials to demonstrate safety
and effectiveness of our product candidates and other positive
results; estimates regarding the total addressable market for our
product candidates; our ability to commercialize our product
candidates, or the effect of delays in commercializing; our
business model and strategic plans for our products, technologies
and business, including our implementation thereof; and those other
risks and uncertainties described in the section titled "Risk
Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2022 and other reports as filed with the SEC.
Forward-looking statements contained in this press release are made
as of this date, and Femasys undertakes no duty to update such
information except as required under applicable law.
Contacts: Investors: Gene
MannheimerIR@femasys.com
Media Contact: Kati WaldenburgMedia@femasys.com
Grafico Azioni Femasys (NASDAQ:FEMY)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Femasys (NASDAQ:FEMY)
Storico
Da Mag 2023 a Mag 2024